LexPharma

Precision science. Pioneering medicine. Patient driven.

[LexPharma @LexPharma]

This week, we’re heading to #ADASciSessions in New Orleans! This year, we’ll share data from our clinical programs in type 1 diabetes and diabetic peripheral neuropathic pain. Learn more: https://t.co/Zb1hGdMtKT

[LexPharma @LexPharma]

We’ll be in NYC for the @Jefferies Healthcare Conference next week, meeting with the healthcare investment community and sharing updates on Lexicon’s work across cardiometabolic disease. For more: https://t.co/krelLAWeig #JefferiesHealthcare

[LexPharma @LexPharma]

Great to be in NYC for the @HCWCO BioConnect Conference, where our team shared updates on our pipeline and work in cardiometabolic disease and pain. Thanks to those who tuned in and connected with us.

[LexPharma @LexPharma]

Painful diabetic peripheral neuropathy affects an estimated 30% of those with type 1 diabetes and 50% of those with type 2 diabetes. Following #PeripheralNeuropathyAwarenessWeek, we’re continuing to elevate patient voices and advance research for unmet needs.

[LexPharma @LexPharma]

We’re participating in the @HCWCO BioConnect Investor Conference this week! Lexicon management will join a fireside chat on May 19 at Nasdaq HQ in NYC. For more: https://t.co/x3Mbe8L5mi #HCWConference

[LexPharma @LexPharma]

This weekend at #ESCCongress, Lexicon will present data from a new SCORED trial analysis exploring heart failure outcomes across cardiac biomarkers.

[LexPharma @LexPharma]

Our Q1 2026 results reflect continued progress across our cardiometabolic and pain pipeline – supporting our focus on advancing programs with the potential to make a meaningful difference for people with unmet needs.
Learn more: https://t.co/j3aumWfiQr

[LexPharma @LexPharma]

Lexicon will report Q1 2026 financial results next week on May 7. Live call & webcast details can be found here: https://t.co/HmjOKJjKEo

[LexPharma @LexPharma]

Glad to be at AAN 2026 this year, where Lexicon shared Phase 2b PROGRESS results supporting a 10 mg dose for Phase 3 development in DPNP, along with new preclinical data. Learn more: https://t.co/zckU2uImPS #AANAM

[LexPharma @LexPharma]

HCMA sat down with Dr. Ahmad Masri recently to discuss the latest clinical trials in HCM - including the SONATA-HCM Phase 3 study of Lexicon’s dual SGLT1/SGLT2 inhibitor - and the evolving HCM research landscape.

Listen to the episode here: https://t.co/PR4kOXiUZ2

[LexPharma @LexPharma]

We’re heading to Chicago for the #AAN Annual Meeting! Lexicon will be onsite engaging with the neurology community and our SVP of Discovery, Suma Gopinathan, PhD, will lead two presentations on our investigational AAK1 inhibitor. Learn more: https://t.co/ePygOk5Rye #AANAM

[LexPharma @LexPharma]

We were pleased to sponsor and join industry peers at the 2026 Texas Life Sciences Summit, connecting with leaders and innovators helping shape the future of life sciences. We left encouraged by the momentum across the industry and energized about the opportunities ahead!

[LexPharma @LexPharma]

SCORED trial data were presented at #ACC26, including an analysis examining heart failure and cardiovascular outcomes across BMI categories in adults with type 2 diabetes and chronic kidney disease.

[LexPharma @LexPharma]

New insights from #ACC26. Dr. Juan Badimon shared Chapter 2 data from the SOTA‑P‑CARDIA trial, building on prior findings in people with HFpEF. Watch the presentation: https://t.co/KHQoXPxkV8

[LexPharma @LexPharma]

We’re heading to @ACCinTouch this week, where data from Lexicon’s clinical programs will be presented in oral and poster sessions, including analyses from the SCORED and SOTA‑P‑CARDIA studies. Learn more: https://t.co/cjAEkdn2LE

[LexPharma @LexPharma]

@NovoNordisk has initiated a Phase 1 clinical study of LX9851, marking continued progress following our 2025 license agreement. Learn more: https://t.co/5DnybvsRGB

[LexPharma @LexPharma]

Chronic pain, including DPNP, doesn’t get the attention it deserves. Dr. Webster’s article advances the conversation on expanding treatment options. He previously joined Lexicon’s Chronic Pain Roundtable on non‑opioid innovation. Read more: https://t.co/aZeidciTma

[LexPharma @LexPharma]

Last November at #AHA Scientific Sessions, Dr. Juan Badimon shared clinical data on our SGLT1/2 inhibitor in HFpEF without diabetes. HFpEF affects over half of the nearly 7M Americans living with heart failure. Explore Chapter 1: https://t.co/Bht6rJD65X Chapter 2 coming soon!

[LexPharma @LexPharma]

At #ATTD2026, we shared a new post hoc analysis of clinical data demonstrating the effect of our SGLT1/2 inhibitor after one year in T1D patients with varying kidney function. We’re proudly working to advance new treatment options for those in the T1D community.

[LexPharma @LexPharma]

We’re excited to be at the @ATTDconf in Barcelona this week! Our team will present data on how kidney function impacts the long-term safety & efficacy of our SGLT1/2 inhibitor in type 1 diabetes. Learn more: https://t.co/kfwqiNRZni